ClinicalTrials.gg
TerminatedNCT02435836Updated Sep 21, 2015Results posted

A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

A Phase 3 interventional study of Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-21.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study terminated when aripiprazole available commercially per protocol

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
631
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
11th of 125
631 · median 130
Started
1998
the only one that year
Phase 3
34 of 126
1 open now
Registered
91st of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 11th largest by enrollment of the 125 interventional ones that give a count, is the only one that started in 1998, is one of 34 in phase 3, and was the 91st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia. Information on the continued efficacy of aripiprazole was also gathered in this long-term trial (until 31 Dec 2012 or until aripiprazole was otherwise available through marketed means and/or reimbursed).

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Complete a Prior Study: each patient must meet one of the following conditions for completion of the prior study:

    • A patient who has completed 52 weeks of post-randomization treatment in the prior double blind study (31-97-301 or 31-98-304-01) is eligible, with no further qualifications.
    • A patient who was early-terminated from the study 31-97-301 or 31-98- 304-01 for either of the following two reasons is eligible to enter this open label study with no minimal required duration of prior double-blind participation:

      • Early termination was due to a marked deterioration of clinical status and no serious adverse events (SAE) other than hospitalization has occurred. The marked clinical deterioration must be documented by at least a one-point increase in CGI-Severity score from the baseline and a score of 6 (much worse) or 7 (very much worse) in CGI-Global Improvement at the time of termination, or
      • Early termination was due to a non-serious AE requiring discontinuation of the study drug
    • A patient who was early terminated after a minimum of 4 weeks' participation in the double-blind treatment in study 31-97-301 or 31-98- 304-01 and the reason for early termination was withdrawal of consent due to lack of effect but not marked deterioration. This must be documented by no change from baseline in the CGI-Severity score and a score of 4 (no change) or 5 (minimally worse) on the CGI-Global Improvement scale.
  2. Signing of Form: Prior to any procedure or drug administration, each patient must sign an informed consent form. In addition, if required by the Ethical Committee, each patient's next-of-kin or responsible caregiver will co-sign the patient's consent form or a separate consent form.

Exclusion criteria

Exclusion Criteria:

  1. Patients suffering from any significant somatic disease or medical problem that would obscure the results of treatment, or that might require frequent changes of concomitant medication.
  2. Patients with any acute or unstable medical condition requiring pharmacotherapy, other than schizophrenia.
  3. Patients with an abnormal laboratory test value in the most recent analysis (from the study 31-97-301 or 31-98-304-01) which is considered by the investigator as presenting a significant risk to the patient for continuing treatment with aripiprazole.
  4. Patients who were early-terminated from the prior double-blind studies (31-97-301 or 31-98-304-01) due to a serious adverse event (SAE) other than worsening of psychosis or hospitalization.
  5. Female patients of child bearing potential with a positive serum pregnancy test at the baseline (last visit of prior study) of this open-label follow-on study.
  6. Patients who have positive result in the urine screen for drugs of abuse (except for cannabis or medically-prescribed analgesics or benzodiazepines.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
631 participants (actual)

Study arms

  • Experimental
    Aripiprazole

    All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.

    Drug: Aripiprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Week

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  2. Mean Change From Baseline in PANSS Positive Sub-scale Score by Week

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  3. Mean Change From Baseline in PANSS Negative Sub-scale Score by Week

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  4. Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) by Week

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  5. Mean Clinical Global Impression of Improvement (CGI-I) by Week

    The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  6. Mean Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. The questionnaire includes questions on the following symptoms. 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The usual cut-off points are: 0 to 6 = normal/ symptom absent, 7 to 19 = mild depression, 20 to 34 = moderate depression, \>34 = severe depression.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  7. Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score by Week

    The SAS is composed of 10 items. This scale contains 10 items: Gait, Arm dropping, Shoulder shaking, Elbow rigidity, Wrist rigidity, Head rotation, Glabella Tap, Tremor, Salivation, Akathisia. Grade of severity of each item is rated using a 5-point scale, 1 (normal) and 5 (most severe). The total score ranges from 10 to 50. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  8. Mean Change From Baseline in Barnes Akathisia Rating Scale Score (BARS) Total Score by Week

    BARS consisted of 4 items: objective observation of akathisia by study physician, subjective feelings of restlessness by participant, participant distress due to akathisia, global evaluation of akathisia. The first 3 items were rated on a 4-point scale: 0 = absence of symptoms to 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). Participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were elicited by direct questioning. The BARS Global Score was derived from the global clinical assessment of akathisia from the BARS panel. Total score ranges from 0 to 14. Negative changes from baseline indicate improvement, with higher negative values indicating better improvement.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  9. Mean Change From Baseline in Abnormal Involuntary Movement Scale Score (AIMS) Total Score by Week

    The AIMS assessment consisted of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest (e.g., in the waiting room), and the study physician would make global judgments on the participant's dyskinesia's (items 8 through 10). For this scale, the participant was seated on a hard, firm chair. These items are rated on a five-point scale: 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). The total score ranges from 0 to 40. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  10. Number of Participants With Adverse Events (AEs)

    The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial.

    Time frame: Baseline to Last Visit

  11. Percentage of Participants With Vital Signs of Potential Clinical Relevance

    The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  12. Percentage of Participants With ECG Measurements of Potential Clinical Relevance

    The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

  13. Percentage of Participants With Laboratory Values of Potential Clinical Relevance

    The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.

    Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit

07

Results

Posted Sep 21, 2015
Limitations and caveats
The study was terminated prematurely by the sponsor. The protocol specified that the study would run until Abilify (aripiprazole) was commercially available in all site countries.

Participant flow

This trial was conducted in 631 participants at 139 trial sites in 23 countries.

Participant flow — Overall Study
MilestoneAripiprazole
Started631
Completed0
Not completed631
Withdrew: Lost to follow-up21
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject236
Withdrew: Insufficient clinical response26
Withdrew: Adverse event44
Withdrew: Sponsor discontinued trial167
Withdrew: Noncompliance27
Withdrew: Protocol violation6
Withdrew: Met withdrawal criteria7
Withdrew: Ae of worsening schizophrenia96

Outcome measures

PrimaryMean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Week

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score by Week
Units on a scaleAripiprazole
Week 1 (N= 619)-1.63 ± 7.92
Week 2 (N= 595)-3.19 ± 9.64
Week 4 (N= 586)-4.27 ± 10.90
Week 6 (N= 573)-4.93 ± 12.07
Week 8 (N= 552)-5.35 ± 13.03
Week 12 (N= 532)-5.47 ± 14.61
Week 16 (N= 517)-6.28 ± 14.44
Week 24 (N= 489)-6.78 ± 14.22
Week 36 (N= 458)-7.22 ± 14.17
Week 48 (N= 426)-8.07 ± 15.72
Week 60 (N= 395)-9.28 ± 14.71
Week 72 (N= 382)-9.81 ± 15.98
Week 84 (N= 362)-10.54 ± 15.92
Week 96 (N= 340)-10.68 ± 16.40
Week 108 (N= 328)-11.46 ± 16.56
Week 120 (N= 316)-11.43 ± 17.01
Week 132 (N= 306)-11.05 ± 17.37
Week 144 (N= 288)-11.70 ± 17.72
Week 156 (N= 279)-11.90 ± 17.47
Week 168 (N= 272)-11.69 ± 17.11
Week 180 (N= 268)-11.83 ± 17.41
Week 192 (N= 255)-11.46 ± 18.00
Week 204 (N= 239)-12.10 ± 17.72
Week 216 (N= 238)-11.54 ± 17.05
Week 228 (N= 224)-12.24 ± 17.53
Week 240 (N= 183)-12.14 ± 19.35
Week 252 (N= 139)-15.19 ± 18.61
Week 264 (N= 83)-22.16 ± 21.07
Week 276 (N= 58)-29.45 ± 20.33
Week 288 (N= 56)-28.79 ± 20.66
Week 300 (N= 55)-21.95 ± 19.91
Week 312 (N= 37)-25.35 ± 18.41
Week 324 (N= 38)-21.95 ± 17.45
Week 336 (N= 28)-24.86 ± 17.78
Week 348 (N= 8)-12.88 ± 14.71
Week 360 (N= 10)-17.70 ± 35.32
Week 372 (N= 3)-10.67 ± 4.16
Week 384 (N= 5)-4.60 ± 9.07
Week 396 (N= 10)-10.10 ± 12.67
Week 408 (N= 9)-5.56 ± 7.06
Week 420 (N= 4)-8.00 ± 2.83
Week 432 (N= 3)-13.67 ± 24.19
Week 444 (N= 1)-28.00 ± NA
Week 456 (N= 4)-48.25 ± 32.12
Week 468 (N= 2)-36.00 ± 2.83
Week 480 (N= 1)-10.00 ± NA
Week 492 (N= 9)-10.00 ± 13.52
Week 504 (N= 2)-9.50 ± 28.99
Week 636 (N= 5)-7.60 ± 22.35
Week 648 (N= 2)-10.00 ± 14.14
Week 660 (N= 3)-15.33 ± 19.66
Week 672 (N= 1)1.00 ± NA
Week 696 (N= 1)-7.00 ± NA
Last Visit (N= 629)-2.30 ± 22.21
PrimaryMean Change From Baseline in PANSS Positive Sub-scale Score by Week

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Positive Sub-scale Score by Week
Units on a scaleAripiprazole
Week 1 (N= 619)-0.39 ± 2.51
Week 2 (N= 595)-0.81 ± 3.15
Week 4 (N= 586)-1.13 ± 3.47
Week 6 (N= 573)-1.23 ± 3.70
Week 8 (N= 552)-1.30 ± 3.97
Week 12 (N= 533)-1.24 ± 4.43
Week 16 (N= 517)-1.43 ± 4.20
Week 24 (N= 489)-1.54 ± 4.26
Week 36 (N= 458)-1.56 ± 4.20
Week 48 (N= 426)-1.73 ± 4.64
Week 60 (N= 395)-2.01 ± 4.32
Week 72 (N= 382)-2.08 ± 4.63
Week 84 (N= 362)-2.26 ± 4.65
Week 96 (N= 340)-2.26 ± 4.81
Week 108 (N= 328)-2.50 ± 4.76
Week 120 (N= 316)-2.45 ± 4.84
Week 132 (N= 306)-2.25 ± 5.02
Week 144 (N= 289)-2.49 ± 5.03
Week 156 (N= 279)-2.46 ± 4.87
Week 168 (N= 272)-2.35 ± 4.62
Week 180 (N= 268)-2.40 ± 4.78
Week 192 (N= 255)-2.22 ± 4.91
Week 204 (N= 239)-2.48 ± 4.86
Week 216 (N= 238)-2.21 ± 4.57
Week 228 (N= 224)-2.42 ± 4.51
Week 240 (N= 183)-2.10 ± 5.16
Week 252 (N= 139)-2.74 ± 4.81
Week 264 (N= 83)-4.24 ± 5.69
Week 276 (N= 58)-5.90 ± 5.80
Week 288 (N= 56)-6.30 ± 5.61
Week 300 (N= 55)-4.16 ± 5.54
Week 312 (N= 37)-5.27 ± 5.57
Week 324 (N= 38)-4.45 ± 5.64
Week 336 (N= 28)-5.46 ± 5.73
Week 348 (N= 8)-0.75 ± 1.04
Week 360 (N= 10)-3.80 ± 7.60
Week 372 (N= 3)-0.67 ± 0.58
Week 384 (N= 5)-0.80 ± 3.96
Week 396 (N= 10)-2.40 ± 3.63
Week 408 (N= 9)-0.89 ± 2.80
Week 420 (N= 4)-0.75 ± 1.50
Week 432 (N= 3)-4.67 ± 8.08
Week 444 (N= 1)-9.00 ± NA
Week 456 (N= 4)-10.50 ± 5.97
Week 468 (N= 2)-6.50 ± 3.54
Week 480 (N= 1)-2.00 ± NA
Week 492 (N= 9)-2.00 ± 2.65
Week 504 (N= 2)-2.50 ± 7.78
Week 636 (N= 5)-1.80 ± 4.02
Week 648 (N= 2)-4.50 ± 7.78
Week 660 (N= 3)-2.00 ± 2.65
Week 672 (N= 1)1.00 ± NA
Week 696 (N= 1)-1.00 ± NA
Last Visit (N= 629)0.23 ± 6.58
PrimaryMean Change From Baseline in PANSS Negative Sub-scale Score by Week

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in PANSS Negative Sub-scale Score by Week
Units on a scaleAripiprazole
Week 1 (N= 619)-0.35 ± 2.18
Week 2 (N= 595)-0.82 ± 2.59
Week 4 (N= 586)-1.05 ± 3.04
Week 6 (N= 573)-1.24 ± 3.38
Week 8 (N= 552)-1.41 ± 3.54
Week 12 (N= 532)-1.54 ± 4.01
Week 16 (N= 517)-1.85 ± 4.12
Week 24 (N= 489)-2.02 ± 4.13
Week 36 (N= 458)-2.16 ± 4.41
Week 48 (N= 426)-2.43 ± 4.71
Week 60 (N= 395)-2.75 ± 4.38
Week 72 (N= 382)-2.94 ± 4.79
Week 84 (N= 362)-3.17 ± 4.87
Week 96 (N= 340)-3.22 ± 4.99
Week 108 (N= 328)-3.36 ± 4.99
Week 120 (N= 316)-3.37 ± 5.25
Week 132 (N= 306)-3.41 ± 5.29
Week 144 (N= 288)-3.58 ± 5.43
Week 156 (N= 279)-3.70 ± 5.27
Week 168 (N= 272)-3.68 ± 5.28
Week 180 (N= 268)-3.69 ± 5.21
Week 192 (N= 255)-3.65 ± 5.40
Week 204 (N= 239)-3.79 ± 5.37
Week 216 (N= 238)-3.74 ± 5.17
Week 228 (N= 224)-3.90 ± 5.38
Week 240 (N= 183)-4.09 ± 5.86
Week 252 (N= 139)-4.88 ± 5.69
Week 264 (N= 83)-6.87 ± 6.50
Week 276 (N= 58)-8.71 ± 6.57
Week 288 (N= 56)-8.32 ± 6.85
Week 300 (N= 55)-6.58 ± 6.42
Week 312 (N= 37)-7.51 ± 5.43
Week 324 (N= 38)-6.63 ± 4.44
Week 336 (N= 28)-7.43 ± 4.59
Week 348 (N= 8)-4.88 ± 5.89
Week 360 (N= 10)-5.60 ± 9.40
Week 372 (N= 3)-4.33 ± 1.53
Week 384 (N= 5)0.00 ± 2.12
Week 396 (N= 10)-2.90 ± 3.67
Week 408 (N= 9)-1.22 ± 2.54
Week 420 (N= 4)-2.25 ± 2.22
Week 432 (N= 3)-2.67 ± 7.51
Week 444 (N= 1)-6.00 ± NA
Week 456 (N= 4)-13.75 ± 9.95
Week 468 (N= 2)-9.00 ± 5.66
Week 480 (N= 1)-5.00 ± NA
Week 492 (N= 9)-2.00 ± 3.61
Week 504 (N= 2)-1.50 ± 12.02
Week 636 (N= 5)-1.80 ± 5.85
Week 648 (N= 2)0.00 ± 0.00
Week 660 (N= 3)-4.67 ± 6.66
Week 672 (N= 1)1.00 ± NA
Week 696 (N= 1)-3.00 ± NA
Last Visit (N= 629)-1.34 ± 6.09
PrimaryMean Change From Baseline in Clinical Global Impression of Severity (CGI-S) by Week

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) by Week
Units on a scaleAripiprazole
Week 1 (N= 619)-0.07 ± 0.49
Week 2 (N= 595)-0.13 ± 0.60
Week 4 (N= 586)-0.20 ± 0.67
Week 6 (N= 573)-0.23 ± 0.78
Week 8 (N= 552)-0.25 ± 0.79
Week 12 (N= 533)-0.25 ± 0.86
Week 16 (N= 517)-0.30 ± 0.86
Week 24 (N= 489)-0.31 ± 0.89
Week 36 (N= 458)-0.32 ± 0.95
Week 48 (N= 426)-0.38 ± 0.94
Week 60 (N= 395)-0.45 ± 0.92
Week 72 (N= 382)-0.45 ± 0.93
Week 84 (N= 362)-0.49 ± 0.95
Week 96 (N= 340)-0.48 ± 0.99
Week 108 (N= 328)-0.51 ± 0.95
Week 120 (N= 316)-0.53 ± 0.98
Week 132 (N= 306)-0.48 ± 1.03
Week 144 (N= 290)-0.52 ± 1.04
Week 156 (N= 279)-0.53 ± 1.00
Week 168 (N= 272)-0.53 ± 0.96
Week 180 (N= 268)-0.55 ± 0.98
Week 192 (N= 255)-0.54 ± 1.04
Week 204 (N= 239)-0.55 ± 1.01
Week 216 (N= 238)-0.53 ± 0.99
Week 228 (N= 232)-0.56 ± 1.00
Week 240 (N= 216)-0.56 ± 1.06
Week 252 (N= 208)-0.58 ± 0.96
Week 264 (N= 194)-0.58 ± 1.04
Week 276 (N= 187)-0.61 ± 1.01
Week 288 (N= 177)-0.64 ± 1.02
Week 300 (N= 167)-0.63 ± 0.99
Week 312 (N= 145)-0.57 ± 1.01
Week 324 (N= 137)-0.60 ± 0.99
Week 336 (N= 121)-0.59 ± 0.95
Week 348 (N= 114)-0.48 ± 0.97
Week 360 (N= 105)-0.54 ± 0.98
Week 372 (N= 93)-0.49 ± 0.94
Week 384 (N= 91)-0.51 ± 0.94
Week 396 (N= 80)-0.53 ± 1.06
Week 408 (N= 69)-0.62 ± 0.96
Week 420 (N= 61)-0.70 ± 1.07
Week 432 (N= 58)-0.69 ± 1.16
Week 444 (N= 51)-0.59 ± 0.96
Week 456 (N= 48)-0.65 ± 1.10
Week 468 (N= 37)-0.46 ± 1.04
Week 480 (N= 33)-0.42 ± 0.83
Week 492 (N= 31)-0.55 ± 0.99
Week 504 (N= 21)-0.57 ± 0.93
Week 516 (N= 19)-0.53 ± 0.84
Week 528 (N= 19)-0.47 ± 0.90
Week 540 (N= 18)-0.61 ± 0.70
Week 552 (N= 18)-0.56 ± 0.86
Week 564 (N= 17)-0.41 ± 0.87
Week 576 (N= 17)-0.35 ± 0.86
Week 588 (N= 17)-0.41 ± 0.87
Week 600 (N= 16)-0.44 ± 0.89
Week 612 (N= 16)-0.44 ± 0.89
Week 624 (N= 16)-0.50 ± 0.73
Week 636 (N= 16)-0.44 ± 0.89
Week 648 (N= 10)-0.70 ± 0.67
Week 660 (N= 8)-0.50 ± 0.53
Week 672 (N= 3)-0.67 ± 0.58
Week 684 (N= 1)-1.00 ± NA
Week 696 (N= 1)-1.00 ± NA
Last Visit (N= 629)-0.00 ± 1.31
PrimaryMean Clinical Global Impression of Improvement (CGI-I) by Week

The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression of Improvement (CGI-I) by Week
Units on a scaleAripiprazole
Week 1 (N= 619)3.60 ± 0.93
Week 2 (N= 595)3.42 ± 0.98
Week 4 (N= 586)3.29 ± 1.02
Week 6 (N= 573)3.21 ± 1.08
Week 8 (N= 552)3.17 ± 1.10
Week 12 (N= 533)3.16 ± 1.12
Week 16 (N= 517)3.08 ± 1.18
Week 24 (N= 489)3.03 ± 1.14
Week 36 (N= 458)2.95 ± 1.14
Week 48 (N= 426)2.88 ± 1.17
Week 60 (N= 395)2.76 ± 1.14
Week 72 (N= 382)2.73 ± 1.11
Week 84 (N= 362)2.67 ± 1.11
Week 96 (N= 340)2.67 ± 1.15
Week 108 (N= 328)2.60 ± 1.12
Week 120 (N= 316)2.58 ± 1.15
Week 132 (N= 306)2.62 ± 1.17
Week 144 (N= 290)2.59 ± 1.20
Week 156 (N= 279)2.58 ± 1.16
Week 168 (N= 272)2.57 ± 1.15
Week 180 (N= 268)2.57 ± 1.16
Week 192 (N= 255)2.59 ± 1.20
Week 204 (N= 239)2.56 ± 1.16
Week 216 (N= 238)2.56 ± 1.20
Week 228 (N= 232)2.49 ± 1.17
Week 240 (N= 216)2.48 ± 1.21
Week 252 (N= 208)2.37 ± 1.13
Week 264 (N= 194)2.14 ± 1.07
Week 276 (N= 187)2.16 ± 1.03
Week 288 (N= 177)2.26 ± 1.06
Week 300 (N= 167)2.26 ± 1.16
Week 312 (N= 145)2.18 ± 1.11
Week 324 (N= 137)2.23 ± 1.05
Week 336 (N= 121)2.03 ± 1.09
Week 348 (N= 114)2.45 ± 1.00
Week 360 (N= 105)2.53 ± 1.36
Week 372 (N= 93)2.14 ± 1.07
Week 384 (N= 91)2.50 ± 1.52
Week 396 (N= 80)3.00 ± 1.63
Week 408 (N= 69)2.50 ± 1.18
Week 420 (N= 61)2.43 ± 1.40
Week 432 (N= 58)2.00 ± 1.73
Week 444 (N= 51)1.00 ± NA
Week 456 (N= 48)1.83 ± 0.75
Week 468 (N= 37)2.00 ± 0.00
Week 480 (N= 33)2.00 ± NA
Week 492 (N= 9)2.33 ± 1.32
Week 504 (N= 2)2.50 ± 2.12
Week 528 (N= 1)4.00 ± NA
Week 636 (N= 5)2.00 ± 0.00
Week 648 (N= 2)1.50 ± 0.71
Week 660 (N= 3)2.33 ± 1.15
Week 672 (N= 3)1.00 ± NA
Week 696 (N= 1)1.00 ± NA
Last Visit (N= 629)3.35 ± 1.60
PrimaryMean Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. The questionnaire includes questions on the following symptoms. 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The usual cut-off points are: 0 to 6 = normal/ symptom absent, 7 to 19 = mild depression, 20 to 34 = moderate depression, \>34 = severe depression.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score
Units on a scaleAripiprazole
Week 1 (N= 619)-0.78 ± 3.62
Week 2 (N= 595)-1.13 ± 4.09
Week 4 (N= 586)-1.38 ± 4.73
Week 6 (N= 572)-1.54 ± 5.15
Week 8 (N= 552)-1.40 ± 4.98
Week 12 (N= 533)-1.31 ± 5.77
Week 16 (N= 517)-1.60 ± 5.41
Week 24 (N= 489)-1.61 ± 5.75
Week 36 (N= 458)-1.66 ± 5.75
Week 48 (N= 425)-1.75 ± 5.47
Week 60 (N= 395)-2.13 ± 5.41
Week 72 (N= 382)-2.21 ± 5.29
Week 84 (N= 362)-2.33 ± 5.51
Week 96 (N= 339)-2.26 ± 5.70
Week 108 (N= 328)-2.30 ± 5.68
Week 120 (N= 316)-2.40 ± 5.67
Week 132 (N= 306)-2.22 ± 5.85
Week 144 (N= 291)-2.47 ± 5.85
Week 156 (N= 279)-2.51 ± 5.64
Week 168 (N= 272)-2.51 ± 5.49
Week 180 (N= 268)-2.73 ± 5.67
Week 192 (N= 255)-2.53 ± 6.05
Week 204 (N= 239)-2.69 ± 6.20
Week 216 (N= 238)-2.50 ± 5.87
Week 228 (N= 224)-2.62 ± 5.82
Week 240 (N= 183)-2.92 ± 6.50
Week 252 (N= 139)-3.63 ± 6.53
Week 264 (N= 83)-5.52 ± 7.89
Week 276 (N= 58)-7.71 ± 8.88
Week 288 (N= 56)-7.57 ± 8.64
Week 300 (N= 55)-6.15 ± 7.52
Week 312 (N= 37)-7.24 ± 8.51
Week 324 (N= 38)-6.32 ± 8.76
Week 336 (N= 28)-7.21 ± 8.01
Week 348 (N= 8)-4.00 ± 7.45
Week 360 (N= 10)-2.80 ± 16.09
Week 372 (N= 3)-2.67 ± 2.08
Week 384 (N= 5)0.00 ± 0.00
Week 396 (N= 10)-1.40 ± 2.95
Week 408 (N= 9)-1.89 ± 1.27
Week 420 (N= 4)0.75 ± 4.11
Week 432 (N= 3)-2.33 ± 5.86
Week 444 (N= 1)-1.00 ± NA
Week 456 (N= 5)-9.60 ± 8.85
Week 468 (N= 2)-3.00 ± 2.83
Week 480 (N= 1)0.00 ± NA
Week 492 (N= 9)-6.56 ± 8.44
Week 504 (N= 2)-13.50 ± 13.44
Week 636 (N= 5)0.40 ± 3.36
Week 648 (N= 2)-1.00 ± 1.41
Week 660 (N= 3)-4.33 ± 2.31
Week 672 (N= 1)-2.00 ± NA
Week 696 (N= 1)-1.00 ± NA
Last Visit (N= 629)-0.31 ± 8.02
PrimaryMean Change From Baseline in Simpson-Angus Scale (SAS) Total Score by Week

The SAS is composed of 10 items. This scale contains 10 items: Gait, Arm dropping, Shoulder shaking, Elbow rigidity, Wrist rigidity, Head rotation, Glabella Tap, Tremor, Salivation, Akathisia. Grade of severity of each item is rated using a 5-point scale, 1 (normal) and 5 (most severe). The total score ranges from 10 to 50. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score by Week
Units on a scaleAripiprazole
Week 1 (N= 618)-0.78 ± 3.05
Week 2 (N= 594)-1.01 ± 3.32
Week 4 (N= 585)-1.06 ± 3.68
Week 6 (N= 572)-1.14 ± 3.94
Week 8 (N= 550)-1.19 ± 4.00
Week 12 (N= 532)-1.28 ± 4.03
Week 16 (N= 516)-1.27 ± 4.18
Week 24 (N= 488)-1.24 ± 3.91
Week 36 (N= 456)-1.10 ± 3.79
Week 48 (N= 426)-1.33 ± 4.14
Week 60 (N= 395)-1.25 ± 3.89
Week 72 (N= 382)-1.36 ± 4.07
Week 84 (N= 362)-1.33 ± 4.16
Week 96 (N= 338)-1.24 ± 3.92
Week 108 (N= 328)-1.29 ± 3.83
Week 120 (N= 316)-1.22 ± 3.83
Week 132 (N= 306)-1.26 ± 3.88
Week 144 (N= 289)-1.26 ± 3.99
Week 156 (N= 278)-1.33 ± 4.04
Week 168 (N= 272)-1.31 ± 3.92
Week 180 (N= 268)-1.43 ± 4.08
Week 192 (N= 255)-1.46 ± 4.07
Week 204 (N= 239)-1.49 ± 4.16
Week 216 (N= 238)-1.39 ± 3.48
Week 228 (N= 224)-1.44 ± 3.55
Week 240 (N= 183)-1.68 ± 3.72
Week 252 (N= 139)-2.11 ± 4.16
Week 264 (N= 83)-2.89 ± 4.99
Week 276 (N= 58)-3.84 ± 5.64
Week 288 (N= 56)-3.88 ± 5.77
Week 300 (N= 55)-2.53 ± 4.55
Week 312 (N= 37)-2.30 ± 4.07
Week 324 (N= 38)-1.76 ± 4.10
Week 336 (N= 28)-1.64 ± 3.90
Week 348 (N= 8)-2.00 ± 2.78
Week 360 (N= 9)-0.44 ± 5.75
Week 372 (N= 3)-1.00 ± 0.00
Week 384 (N= 5)-0.20 ± 0.45
Week 396 (N= 10)-0.30 ± 1.16
Week 408 (N= 9)-0.89 ± 1.27
Week 420 (N= 4)-1.25 ± 1.50
Week 432 (N= 3)-1.00 ± 1.73
Week 444 (N= 1)1.00 ± NA
Week 456 (N= 5)-7.20 ± 8.87
Week 468 (N= 2)0.00 ± 0.00
Week 480 (N= 1)-1.00 ± NA
Week 492 (N= 9)-3.22 ± 5.33
Week 504 (N= 2)-3.00 ± 4.24
Week 636 (N= 5)-0.20 ± 0.45
Week 648 (N= 2)0.00 ± 0.00
Week 660 (N= 3)-1.00 ± 1.00
Week 672 (N= 1)-3.00 ± NA
Week 696 (N= 1)-7.00 ± NA
Last Visit (N= 628)-1.36 ± 4.31
PrimaryMean Change From Baseline in Barnes Akathisia Rating Scale Score (BARS) Total Score by Week

BARS consisted of 4 items: objective observation of akathisia by study physician, subjective feelings of restlessness by participant, participant distress due to akathisia, global evaluation of akathisia. The first 3 items were rated on a 4-point scale: 0 = absence of symptoms to 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). Participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were elicited by direct questioning. The BARS Global Score was derived from the global clinical assessment of akathisia from the BARS panel. Total score ranges from 0 to 14. Negative changes from baseline indicate improvement, with higher negative values indicating better improvement.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Barnes Akathisia Rating Scale Score (BARS) Total Score by Week
Units on a scaleAripiprazole
Week 1 (N= 618)-0.15 ± 0.67
Week 2 (N= 595)-0.20 ± 0.70
Week 4 (N= 586)-0.20 ± 0.74
Week 6 (N= 572)-0.23 ± 0.76
Week 8 (N= 552)-0.22 ± 0.79
Week 12 (N= 533)-0.22 ± 0.78
Week 16 (N= 517)-0.22 ± 0.77
Week 24 (N= 489)-0.22 ± 0.74
Week 36 (N= 458)-0.21 ± 0.75
Week 48 (N= 425)-0.20 ± 0.75
Week 60 (N= 395)-0.20 ± 0.70
Week 72 (N= 382)-0.19 ± 0.73
Week 84 (N= 362)-0.21 ± 0.74
Week 96 (N= 340)-0.21 ± 0.79
Week 108 (N= 327)-0.21 ± 0.77
Week 120 (N= 316)-0.20 ± 0.75
Week 132 (N= 306)-0.22 ± 0.76
Week 144 (N= 291)-0.22 ± 0.79
Week 156 (N= 278)-0.24 ± 0.79
Week 168 (N= 272)-0.22 ± 0.78
Week 180 (N= 268)-0.24 ± 0.81
Week 192 (N= 255)-0.29 ± 0.79
Week 204 (N= 238)-0.29 ± 0.80
Week 216 (N= 237)-0.26 ± 0.76
Week 228 (N= 223)-0.26 ± 0.78
Week 240 (N= 183)-0.24 ± 0.75
Week 252 (N= 139)-0.29 ± 0.81
Week 264 (N= 83)-0.51 ± 1.06
Week 276 (N= 58)-0.69 ± 1.16
Week 288 (N= 56)-0.64 ± 1.09
Week 300 (N= 55)-0.51 ± 0.96
Week 312 (N= 37)-0.35 ± 0.68
Week 324 (N= 38)-0.26 ± 0.60
Week 336 (N= 28)-0.29 ± 0.66
Week 348 (N= 8)-0.75 ± 1.04
Week 360 (N= 9)-0.22 ± 0.67
Week 372 (N= 3)0.00 ± 0.00
Week 384 (N= 5)0.00 ± 0.00
Week 396 (N= 10)-0.10 ± 0.32
Week 408 (N= 9)-0.33 ± 0.71
Week 420 (N= 4)-0.25 ± 0.50
Week 432 (N= 3)0.00 ± 0.00
Week 444 (N= 1)0.00 ± NA
Week 456 (N= 5)-1.40 ± 1.67
Week 468 (N= 2)0.00 ± 0.00
Week 480 (N= 1)0.00 ± NA
Week 492 (N= 9)-0.56 ± 1.01
Week 504 (N= 2)-1.50 ± 0.71
Week 636 (N= 5)-0.40 ± 0.89
Week 648 (N= 2)0.00 ± 0.00
Week 660 (N= 3)-0.67 ± 1.15
Week 672 (N= 1)-4.00 ± NA
Week 696 (N= 1)0.00 ± NA
Last Visit (N= 629)-0.26 ± 0.85
PrimaryMean Change From Baseline in Abnormal Involuntary Movement Scale Score (AIMS) Total Score by Week

The AIMS assessment consisted of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while the participant was at rest (e.g., in the waiting room), and the study physician would make global judgments on the participant's dyskinesia's (items 8 through 10). For this scale, the participant was seated on a hard, firm chair. These items are rated on a five-point scale: 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). The total score ranges from 0 to 40. Negative changes from baseline indicate an improvement, with higher negative values indicating better improvement.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Abnormal Involuntary Movement Scale Score (AIMS) Total Score by Week
Units on a scaleAripiprazole
Week 1 (N= 619)-0.21 ± 1.61
Week 2 (N= 595)-0.29 ± 1.77
Week 4 (N= 586)-0.28 ± 1.96
Week 6 (N= 572)-0.34 ± 2.25
Week 8 (N= 552)-0.34 ± 2.22
Week 12 (N= 533)-0.37 ± 2.26
Week 16 (N= 517)-0.39 ± 2.31
Week 24 (N= 489)-0.35 ± 2.08
Week 36 (N= 458)-0.21 ± 1.85
Week 48 (N= 425)-0.35 ± 2.17
Week 60 (N= 395)-0.33 ± 2.02
Week 72 (N= 382)-0.31 ± 2.10
Week 84 (N= 362)-0.31 ± 2.12
Week 96 (N= 340)-0.25 ± 1.84
Week 108 (N= 328)-0.27 ± 1.88
Week 120 (N= 316)-0.26 ± 1.85
Week 132 (N= 306)-0.26 ± 1.91
Week 144 (N= 290)-0.29 ± 1.97
Week 156 (N= 279)-0.31 ± 2.04
Week 168 (N= 272)-0.29 ± 1.87
Week 180 (N= 268)-0.34 ± 2.08
Week 192 (N= 255)-0.35 ± 2.08
Week 204 (N= 239)-0.30 ± 2.06
Week 216 (N= 238)-0.26 ± 1.50
Week 228 (N= 224)-0.31 ± 1.41
Week 240 (N= 183)-0.31 ± 1.44
Week 252 (N= 139)-0.40 ± 1.59
Week 264 (N= 83)-0.61 ± 1.95
Week 276 (N= 58)-0.76 ± 2.30
Week 288 (N= 56)-0.57 ± 2.72
Week 300 (N= 55)-0.18 ± 1.45
Week 312 (N= 37)-0.35 ± 0.68
Week 324 (N= 38)-0.32 ± 0.57
Week 336 (N= 28)-0.36 ± 0.56
Week 348 (N= 8)-0.50 ± 1.07
Week 360 (N= 9)-0.44 ± 0.73
Week 372 (N= 3)0.00 ± 0.00
Week 384 (N= 5)0.00 ± 0.00
Week 396 (N= 10)0.00 ± 0.00
Week 408 (N= 9)0.00 ± 0.00
Week 420 (N= 4)0.00 ± 0.00
Week 432 (N= 3)0.00 ± 0.00
Week 444 (N= 1)0.00 ± NA
Week 456 (N= 5)-1.00 ± 2.24
Week 468 (N= 2)0.00 ± 0.00
Week 480 (N= 1)0.00 ± NA
Week 492 (N= 9)-0.44 ± 0.53
Week 504 (N= 2)-0.50 ± 0.71
Week 636 (N= 5)0.20 ± 0.45
Week 648 (N= 2)0.00 ± 0.00
Week 660 (N= 3)0.00 ± 0.00
Week 672 (N= 1)0.00 ± NA
Week 696 (N= 1)0.00 ± NA
Last Visit (N= 629)-0.39 ± 2.36
PrimaryNumber of Participants With Adverse Events (AEs)

The AEs were one of the primary parameters to measure the safety and tolerability of individual participants. The AEs were captured for all participants from the time the ICF was signed until the end of the trial.

Time frame:
Baseline to Last Visit
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAripiprazole
Participants with serious TEAEs179
Participants with severe TEAEs116
Participants discontinued medication due to AE140
Participants with TEAEs523
Participants discontinued due to AEs or death140
PrimaryPercentage of Participants With Vital Signs of Potential Clinical Relevance

The vital signs were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance included abnormal values in heart rate, systolic and diastolic blood pressure, respiratory rate and weight that were identified based on pre-defined criteria.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Number · percentage of participants
Percentage of Participants With Vital Signs of Potential Clinical Relevance
percentage of participantsAripiprazole
Heart rate sitting increase ≥15 bpm (N=625)0.5
Systolic sitting BP increase ≥20 mmHg (N=627)0.8
Systolic sitting BP decrease ≥20 mmHg (N=627)1.3
Diastolic sitting BP increase ≥15mmHg (N=627)3.0
Weight gain ≥7% (N=622)38.9
Weight loss ≥7% (N=622)23.6
PrimaryPercentage of Participants With ECG Measurements of Potential Clinical Relevance

The measurement of ECG was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Number · Percentage of participants
Percentage of Participants With ECG Measurements of Potential Clinical Relevance
Percentage of participantsAripiprazole
Tachycardia (N=612)0.8
Bradycardia (N=612)7.5
Sinus tachycardia (N=612)0.8
Sinus bradycardia (N=612)7.4
Ventricular premature beat (N=612)2.9
Primary atrioventricular block (N=606)2.5
Secondary atrioventricular block (N=612)0.2
Left bundle branch block (N=612)0.2
Right bundle branch block (N=612)16.0
Pre-excitation syndrome (N=612)0.3
Other intraventricular conduction block (N=611)1.8
Acute infarction (N=612)0.2
Old infarction (N=612)0.7
QTcB (N=612)8.0
QTcF (N=611)2.1
QTcN (N=611)2.3
PrimaryPercentage of Participants With Laboratory Values of Potential Clinical Relevance

The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.

Time frame:
Baseline, Weeks 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108 continuing every 12 weeks, Last Visit
Reported as:
Number · Percentage of participants
Percentage of Participants With Laboratory Values of Potential Clinical Relevance
Percentage of participantsAripiprazole
Alanine aminotransferase (IU/L) (N=626)1.1
Aspartate aminotransferase (IU/L) (N=626)1.0
Bilirubin (mg/dl) (high)(N=626)3.0
Calcium (mg/dl) (low) (N=626)3.4
Chloride (meq/l) (low) (N=626)0.5
Chloride (meq/l) (high) (N=626)0.2
Creatinine phosphokinase (IU/L) (N=626)14.9
Creatinine (mg/dl) (N=617)0.5
Glucose (mg/dl) (N=626)3.0
Lactic dehydrogenase (IU/L) (N=626)0.2
Potassium (meq/l) (low) (N=626)0.2
Potassium (meq/l) (high) (N=626)5.3
Sodium (meq/l) (low) (N=626)0.5
Sodium (meq/l) (high) (N=626)0.2
Urea nitrogen (mg/dl) (N=626)0.8
Uric acid (mg/dl) (N=626)1.0
Eosinophils (%) (N=624)3.2
Hematocrit (%) (N=623)2.7
Hemoglobin (g/dl) (N=625)2.4
Platelet count (per cubic mm) (low) (N=625)0.2
Platelet count (per cubic mm) (high) (N=625)0.3
White blood count (thou/mcl) (low) (N=625)1.1
White blood count (thou/mcl) (high) (N=625)3.8
Glucose, urine (N=613)1.6
Protein, urine (N=599)1.8

Adverse events

Collected over From the signing of the informed consent to 30 days after the end of study treatment. The investigator continued to report any significant follow-up information on the AE up to the time the event had been resolved.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—179/631 (28.4%)364/631 (57.7%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventAripiprazole
SchizophreniaPsychiatric disorders85/631
Psychotic disorderPsychiatric disorders20/631
Social stay hospitalisationSocial circumstances16/631
AnxietyPsychiatric disorders10/631
Suicidal attemptPsychiatric disorders6/631
AgressionPsychiatric disorders4/631
Completed suicidePsychiatric disorders4/631
HallucinationPsychiatric disorders4/631
OverdoseInjury, poisoning and procedural complications3/631
Cardiac failureCardiac disorders2/631
Most frequent other events
Most frequent other events
EventAripiprazole
InsomniaPsychiatric disorders118/631
AkathisiaNervous system disorders84/631
SchizophreniaPsychiatric disorders79/631
AnxietyPsychiatric disorders73/631
Weight increasedInvestigations56/631
Extrapyramidal disorderNervous system disorders50/631
TremorNervous system disorders50/631
HeadacheNervous system disorders48/631
InfluenzaInfections and infestations47/631

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole
Mean37.5 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole
Female264
Male367
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1998, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2015
First posted
May 6, 2015
Start
Apr 1998
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Sep 21, 2015
Last update
Sep 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02435836
Responsible party
Sponsor
First posted
May 6, 2015
Start date
Apr 1998
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Sep 21, 2015
Last update
Sep 21, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion